keyword
MENU ▼
Read by QxMD icon Read
search

Sbrt lung cancer

keyword
https://www.readbyqxmd.com/read/29121047/dosimetric-comparison-of-ct-guided-iodine-125-seed-stereotactic-brachytherapy-and-stereotactic-body-radiation-therapy-in-the-treatment-of-nsclc
#1
Ranran Li, Ying Zhang, Yuan Yuan, Qi Lin, Jianjian Dai, Ruicai Xu, Xudong Hu, Mingyong Han
This study aimed to assess the dosimetric differences between iodine-125 seed stereotactic brachytherapy (SBT) and stereotactic body radiation therapy (SBRT) in the treatment of non-small cell lung cancer (NSCLC). An SBT plan and an SBRT plan were generated for eleven patients with T1-2 NSCLC. Prescription of the dose and fractionation (fr) for SBRT was 48Gy/4fr. The planning aim for SBT was D90 (dose delivered to 90% of the target volume)≥120Gy. Student's paired t test was used to compare the dosimetric parameters...
2017: PloS One
https://www.readbyqxmd.com/read/29106810/stereotactic-body-radiotherapy-for-early-stage-non-small-cell-lung-cancer-american-society-of-clinical-oncology-endorsement-of-the-american-society-for-radiation-oncology-evidence-based-guideline
#2
Bryan J Schneider, Megan E Daly, Erin B Kennedy, Mara B Antonoff, Stephen Broderick, Jill Feldman, Shruti Jolly, Bryan Meyers, Gaetano Rocco, Chad Rusthoven, Ben J Slotman, Daniel H Sterman, Brendon M Stiles
Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on treatment with stereotactic body radiotherapy (SBRT) for patients with early-stage non-small-cell lung cancer. ASCO has a policy and set of procedures for endorsing and/or adapting clinical practice guidelines that have been developed by other professional organizations. Methods The ASTRO Evidence-Based Guideline for Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer was reviewed for developmental rigor by methodologists...
November 6, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29066121/patterns-of-intraosseous-recurrence-after-stereotactic-body-radiation-therapy-for-coxal-bone-metastasis
#3
Kei Ito, Takuya Shimizuguchi, Keiji Nihei, Tomohisa Furuya, Hiroaki Ogawa, Hiroshi Tanaka, Keisuke Sasai, Katsuyuki Karasawa
PURPOSE: To analyze the detailed pattern of intraosseous failure after stereotactic body radiation therapy (SBRT) for coxal bone metastasis. METHODS AND MATERIALS: Patients treated with SBRT to coxal bone metastasis were identified by retrospective chart review. The SBRT doses were 30 Gy or 35 Gy in 5 fractions. A margin of 5 to 10 mm was added to the gross tumor volume to create the clinical target volume. We evaluated the presence or absence of intraosseous recurrence using magnetic resonance imaging...
September 5, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29064573/effects-of-magnetic-field-orientation-and-strength-on-the-treatment-planning-of-non-small-cell-lung-cancer
#4
Schrenk Oliver, Spindeldreier Claudia Katharina, Burigo Lucas Norberto, Hoerner-Rieber Juliane, Pfaffenberger Asja
PURPOSE: Magnetic resonance image-guided radiotherapy (MRgRT) has the potential to increase the accuracy of radiation treatment delivery. Several research groups have developed hybrid MRgRT devices differing by radiation source used, magnetic field orientation and strength. In this work, we investigate the impact of different magnetic field orientations and strengths on the treatment planning of non-small cell lung cancer patients (NSCLC). METHODS: A framework using the in-house developed treatment planning system matRad and the EGSnrc Monte Carlo code system was introduced to perform Monte Carlo based treatment planning in the presence of a magnetic field...
October 24, 2017: Medical Physics
https://www.readbyqxmd.com/read/29052514/five-fraction-sbrt-for-ultra-central-nsclc-in-field-recurrences-following-high-dose-conventional-radiation
#5
Michael C Repka, Nima Aghdam, Shaan K Kataria, Lloyd Campbell, Simeng Suy, Sean P Collins, Eric Anderson, Jonathan W Lischalk, Brian T Collins
PURPOSE/OBJECTIVE: Local treatment options for patients with in-field non-small cell lung cancer (NSCLC) recurrence following conventionally fractionated external beam radiation therapy (CF-EBRT) are limited. Stereotactic body radiation therapy (SBRT) is a promising modality to achieve reasonable local control, although toxicity remains a concern. MATERIALS/METHODS: Patients previously treated with high-dose CF-EBRT (≥59.4 Gy, ≤3 Gy/fraction) for non-metastatic NSCLC who underwent salvage SBRT for localized ultra-central in-field recurrence were included in this analysis...
October 19, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/29036692/clinical-utility-of-texture-analysis-of-18f-fdg-pet-ct-in-patients-with-stage-i-lung-cancer-treated-with-stereotactic-body-radiotherapy
#6
Kazuya Takeda, Kentaro Takanami, Yuko Shirata, Takaya Yamamoto, Noriyoshi Takahashi, Kengo Ito, Kei Takase, Keiichi Jingu
We evaluated the reproducibility and predictive value of texture parameters and existing parameters of 18F-FDG PET/CT images in Stage I non-small-cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT). Twenty-six patients with Stage I NSCLC (T1-2N0M0) were retrospectively analyzed. All of the patients underwent an 18F-FDG PET/CT scan before treatment and were treated with SBRT. Each tumor was delineated using PET Edge (MIM Software Inc., Cleveland, OH), and texture parameters were calculated using open-source code CGITA...
September 21, 2017: Journal of Radiation Research
https://www.readbyqxmd.com/read/28985095/a-propensity-matched-analysis-of-outcomes-of-patients-with-clinical-stage-i-non-small-cell-lung-cancer-treated-surgically-or-with-stereotactic-radiotherapy-a-meta-analysis
#7
Shi-Wang Wen, Li Han, Hui-Lai Lv, Yan-Zhao Xu, Zhen-Hua Li, Ming-Bo Wang, Yong-Gang Zhu, Peng Su, Zi-Qiang Tian, Yue-Feng Zhang
OBJECTIVE: The aim of this study was to compare the efficacy between SBRT and surgery based on the Propensity-Matched Analysis. METHODS: Publications on comparison SBRT and Surgery for early stage non- small cell lung cancer (NSCLC) from 2011 to 2017 were collected. Propensity score matching was used to achieve comparable treatment hazard ratios of the overall survival (OS), local control survival (LC), regional control survival (RC), loco-regional control survival (LRC), distant control survival (DC), disease-free survival (DFS), and progression-free survival (PFS) between SBRT and Surgery...
October 6, 2017: Journal of Investigative Surgery: the Official Journal of the Academy of Surgical Research
https://www.readbyqxmd.com/read/28975083/parenchymal-and-functional-lung-changes-after-stereotactic-body-radiotherapy-for-early-stage-non-small-cell-lung-cancer-experiences-from-a-single-institution
#8
Juliane Hörner-Rieber, Julian Dern, Denise Bernhardt, Laila König, Sebastian Adeberg, Vivek Verma, Angela Paul, Jutta Kappes, Hans Hoffmann, Juergen Debus, Claus P Heussel, Stefan Rieken
INTRODUCTION: This study aimed to evaluate parenchymal and functional lung changes following stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) patients and to correlate radiological and functional findings with patient and treatment characteristics as well as survival. MATERIALS AND METHODS: Seventy patients with early-stage NSCLC treated with SBRT from 2004 to 2015 with more than 1 year of CT follow-up scans were analyzed...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28958106/-stereotactic-body-radiotherapy-for-early-stage-nsclc-what-is-the-evidence
#9
Matthias Guckenberger
Stereotactic body radiotherapy (SBRT) was first described in the mid 90s as a technique using high precision radiotherapy to deliver escalated, ablative irradiation doses and which simultaneously minimised incidental irradiation of healthy tissue. Technological and clinical development of this technique has been pioneered in the field of early stage non-small cell lung cancer, where improved local tumor control led to prolonged overall survival. Today, SBRT is the evidence-based and guideline-recommended treatment of choice for early stage NSCLC in patients who are medically inoperable...
September 2017: Zentralblatt Für Chirurgie
https://www.readbyqxmd.com/read/28951090/improved-survival-of-stage-i-non-small-cell-lung-cancer-a-va-central-cancer-registry-analysis
#10
Matthew J Boyer, Christina D Williams, David H Harpole, Mark W Onaitis, Michael J Kelley, Joseph K Salama
INTRODUCTION: The combined impact of advances in diagnosis and treatment of stage I NSCLC has not been assessed comprehensively. To define the survival impact of modern staging and treatment techniques for clinical stage I NSCLC, the Veterans Administration Central Cancer Registry, a database of U.S. veterans in whom the disease was diagnosed in the Veteran's Health Administration, was queried. From this database, patients who had stage I NSCLC diagnosed from 2001 to 2010 and were treated with either surgery or radiation were identified...
September 23, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28946909/ct-imaging-features-associated-with-recurrence-in-non-small-cell-lung-cancer-patients-after-stereotactic-body-radiotherapy
#11
Qian Li, Jongphil Kim, Yoganand Balagurunathan, Jin Qi, Ying Liu, Kujtim Latifi, Eduardo G Moros, Matthew B Schabath, Zhaoxiang Ye, Robert J Gillies, Thomas J Dilling
BACKGROUND: Predicting recurrence after stereotactic body radiotherapy (SBRT) in non-small cell lung cancer (NSCLC) patients is problematic, but critical for the decision of following treatment. This study aims to investigate the association of imaging features derived from the first follow-up computed tomography (CT) on lung cancer patient outcomes following SBRT, and identify patients at high risk of recurrence. METHODS: Fifty nine biopsy-proven non-small cell lung cancer patients were qualified for this study...
September 25, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28943046/radical-radiation-therapy-for-oligometastatic-breast-cancer-results-of-a-prospective-phase-ii-trial
#12
Marco Trovo, Carlo Furlan, Jerry Polesel, Francesco Fiorica, Stefano Arcangeli, Niccolò Giaj-Levra, Filippo Alongi, Alessandro Del Conte, Loredana Militello, Elena Muraro, Debora Martorelli, Simon Spazzapan, Massimiliano Berretta
BACKGROUND AND PURPOSE: We conducted a prospective phase II multicentric trial to determine if radical radiation therapy to all metastatic sites might improve the progression-free survival (PFS) in oligometastatic breast cancer patients. Secondary endpoints were local control (LC), overall survival (OS) and toxicity. METHODS AND MATERIALS: Inclusion criteria were the following: oligometastatic breast cancer with ≤5 metastatic sites, FDG-PET/CT staging, no brain metastases, primary tumor controlled...
September 21, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28941961/survival-impact-of-cardiac-dose-following-lung-stereotactic-body-radiotherapy
#13
Olive Y Wong, Vivian Yau, Julie Kang, Daniel Glick, Patricia Lindsay, Lisa W Le, Alexander Sun, Andrea Bezjak, B C John Cho, Andrew Hope, Meredith Giuliani
INTRODUCTION: The purpose of this study was to determine the impact of radiation dose to substructures of the heart in lung stereotactic body radiotherapy (SBRT) patients on non-cancer-related deaths. METHODS: Patients treated with lung SBRT at a single institution from 2005 to 2013 were included. The heart and its substructures were contoured, and dose was calculated including mean, max, and max 10 cc dose. Clinical variables including stage, histology, age, gender, Charlson comorbidity index (CCI), preexisting cardiac disease, pulmonary function (forced expiratory volume in 1 second, diffusion capacity), and smoking status were explored for association with non-cancer-related deaths in univariable (UVA) and multivariable (MVA) analyses...
August 31, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28941581/use-of-frailty-to-predict-survival-in-elderly-patients-with-early-stage-non-small-cell-lung-cancer-treated-with-stereotactic-body-radiation-therapy
#14
Idalid Franco, Yu-Hui Chen, Fallon Chipidza, Vishesh Agrawal, John Romano, Elizabeth Baldini, Aileen Chen, Yolonda Colson, Ying Hou, David Kozono, Jon Wee, Raymond Mak
OBJECTIVES: Frailty has been shown to increase morbidity and mortality independent of age, but studies are lacking in radiation oncology. This study evaluates a modified frailty index (mFI) in predicting overall survival (OS) and non-cancer death for Stage I/II [N0M0] Non-Small-Cell Lung Cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT). MATERIALS AND METHODS: Medical records for all patients with Stage I/II NSCLC treated at our institution with SBRT from 2009 to 2014 were reviewed...
September 20, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28934231/principal-component-analysis-identifies-patterns-of-cytokine-expression-in-non-small-cell-lung-cancer-patients-undergoing-definitive-radiation-therapy
#15
Susannah G Ellsworth, Bryan M Rabatic, Jie Chen, Jing Zhao, Jeffrey Campbell, Weili Wang, Wenhu Pi, Paul Stanton, Martha Matuszak, Shruti Jolly, Amy Miller, Feng-Ming Kong
BACKGROUND/PURPOSE: Radiation treatment (RT) stimulates the release of many immunohumoral factors, complicating the identification of clinically significant cytokine expression patterns. This study used principal component analysis (PCA) to analyze cytokines in non-small cell lung cancer (NSCLC) patients undergoing RT and explore differences in changes after hypofractionated stereotactic body radiation therapy (SBRT) and conventionally fractionated RT (CFRT) without or with chemotherapy...
2017: PloS One
https://www.readbyqxmd.com/read/28929083/emerging-therapies-for-stage-iii-non-small-cell-lung-cancer-stereotactic-body-radiation-therapy-and-immunotherapy
#16
REVIEW
Sameera S Kumar, Kristin A Higgins, Ronald C McGarry
The current standard of care for locally advanced non-small cell lung cancer (NSCLC) includes radiation, chemotherapy, and surgery in certain individualized cases. In unresectable NSCLC, chemoradiation has been the standard of care for the past three decades. Local and distant failure remains high in this group of patients, so dose escalation has been studied in both single institution and national clinical trials. Though initial studies showed a benefit to dose escalation, phase III studies examining dose escalation using standard fractionation or hyperfractionation have failed to show a benefit...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28919394/concomitant-chemotherapy-and-radiotherapy-with-sbrt-boost-for-unresectable-stage-iii-non-small-cell-lung-cancer-a-phase-i-study
#17
Kristin A Higgins, Rathi N Pillai, Zhengjia Chen, Sibo Tian, Chao Zhang, Pretesh Patel, Suchita Pakkala, Jay Shelton, Seth D Force, Felix G Fernandez, Conor E Steuer, Taofeek K Owonikoko, Suresh S Ramalingam, Jeffrey D Bradley, Walter J Curran
OBJECTIVES: Stereotactic body radiation therapy (SBRT) is now the standard of care in medically inoperable stage I NSCLC, yielding high rates of local control. It is unknown whether SBRT can be safely utilized in the locally advanced NSCLC setting. This multi-institution phase I study evaluated the safety of 44 Gy of conventionally fractionated thoracic radiation with concurrent chemotherapy plus dose-escalated SBRT boost to both the primary tumor and involved mediastinal lymph nodes...
November 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28919006/histology-of-non-small-cell-lung-cancer-predicts-the-response-to-stereotactic-body-radiotherapy
#18
Juliane Hörner-Rieber, Denise Bernhardt, Julian Dern, Laila König, Sebastian Adeberg, Angela Paul, Claus Peter Heussel, Jutta Kappes, Hans Hoffmann, Felix J P Herth, Jürgen Debus, Arne Warth, Stefan Rieken
BACKGROUND AND PURPOSE: To investigate the prognostic impact of different histological subtypes of non-small cell lung cancer (NSCLC) on outcome following stereotactic body radiotherapy (SBRT) for NSCLC patients. MATERIALS AND METHODS: We analyzed 126 consecutive patients with early-stage adenocarcinoma or squamous cell carcinoma treated with SBRT from 2004 to 2016. Adenocarcinoma patients were further sub-classified as high-risk or low-risk tumors. RESULTS: With a median follow-up time of 22months, 2-year overall survival (OS), local (LC), and distant control (DC) were 68%, 90% and 79%, respectively...
September 14, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28919004/stereotactic-body-radiotherapy-for-lung-cancer-patients-with-idiopathic-interstitial-pneumonias
#19
Yuichiro Tsurugai, Atsuya Takeda, Naoko Sanuki, Tatsuji Enomoto, Takeshi Kaneko, Yu Hara, Tomikazu Mizuno, Noriyuki Saeki, Yousuke Aoki, Yohei Oku, Takeshi Akiba, Etsuo Kunieda
PURPOSE: To compare toxicity and survival after stereotactic body radiotherapy (SBRT) between lung cancer patients with or without idiopathic interstitial pneumonias (IIPs), and to investigate the potential value of SBRT for the patients. METHODS: Among lung cancer patients receiving SBRT between 2005 and 2016, we evaluated those treated with a total dose of 40-60Gy in five fractions with curative intent who either were staged as cT1-4N0M0 or experienced postoperative isolated local recurrence...
September 14, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28917258/stereotactic-body-radiotherapy-for-early-stage-lung-cancer-historical-developments-and-future-strategies
#20
Kevin L M Chua, Iris Sin, Kam W Fong, Melvin L K Chua, Hiroshi Onishi
The application of radiosurgery dose escalation extra-cranially in a moving target, surrounded by critical normal tissue, presents unique dosimetric and clinical challenges. Building on a strong foundation of robust technological advancements and well-planned clinical studies, lung stereotactic body radiotherapy (SBRT) has firmly established its place in the management of early stage non-small cell lung cancer (NSCLC). Nevertheless, favourable outcomes and long-term survival still evade a substantial proportion of patients, especially for central and larger peripheral lung tumours...
September 2017: Chinese Clinical Oncology
keyword
keyword
107556
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"